The Biomedical Advanced Research and Development Authority (BARDA) is doing its part to combat the global problem of antimicrobial resistance (AMR) by incentivizing investments in new antibiotics, including funding through the drug development accelerator CARB-X.
Antimicrobial Incentives
For Part 1 of this roundtable discussion, see:
AMR Roundtable: The Push And Pull Of Antimicrobial Development Incentives (Part 1)
The Pink Sheet spoke with BARDA's Acting Deputy Director Joe Larsen about CARB-X and other ways of providing incentives and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?